How does Dexmedetomidine Hydrochloride affect the cardiovascular system?

Dexmedetomidine Hydrochloride is a medication used for sedation in critial care patients and procedural sedation. It is a selective α2-adrenergic receptor agonist and is known for its sedative properties. Dexmedetomidine Hydrochloride is sold under the brand name Precedex, and it is administered intravenously. This medication is commonly used in intensive care units for its ability to reduce anxiety and promote sleep without causing respiratory depression.

How does Dexmedetomidine Hydrochloride affect the cardiovascular system?

What are the sedative properties of Dexmedetomidine Hydrochloride?

What dosage of Dexmedetomidine Hydrochloride is typically used for sedation?

What are the risks associated with using Dexmedetomidine Hydrochloride?

Dexmedetomidine Hydrochloride has been shown to have a minimal effect on the cardiovascular system, making it an attractive option for use in critically ill patients. Unlike other sedatives, it does not cause respiratory depression and can actually improve respiratory function. Dexmedetomidine Hydrochloride has also been shown to reduce delirium and cognitive dysfunction in critically ill patients. The sedative properties of Dexmedetomidine Hydrochloride make it an excellent choice for procedural sedation. It has a rapid onset of action and can produce a deep level of sedation. Dexmedetomidine Hydrochloride has also been shown to decrease opioid requirements during surgery. The dosage of Dexmedetomidine Hydrochloride used for sedation varies based on the patient's age, weight, and medical history. Typically, a loading dose is administered followed by a maintenance dose. Dosages range from 0.2 to 0.7 μg/kg/h. The risks associated with using Dexmedetomidine Hydrochloride include hypotension, bradycardia, and sinus arrest. These side effects are typically dose-dependent and can be managed with appropriate doses and close monitoring. In summary, Dexmedetomidine Hydrochloride is a useful medication for sedation in critically ill patients and procedural sedation. Its sedative properties make it an excellent choice for these applications, and it has been shown to have a minimal effect on the cardiovascular system. However, potential side effects must be closely monitored and managed.

Jiangsu Run'an Pharmaceutical Co. Ltd. is a pharmaceutical company that specializes in the research and development, production, and sales of anesthesia and analgesic drugs. With a focus on quality and innovation, we strive to provide safe and effective medications to improve patient outcomes. Contact us at wangjing@ctqjph.com to learn more.

Research Papers:

Bergese SD, Ramaswamy Kanoria Narla A, Michel M et al. Efficacy and Safety of Dexmedetomidine for the Management of Intensive Care Unit Delirium: A Narrative Review. Ochsner J. 2019 Fall; 19(3): 197–204.

Liu Y, Xu J, Guo Q et al. The Effect of Dexmedetomidine on Early Postoperative Cognitive Dysfunction and Serum Cytokine Levels: A Prospective Randomized Controlled Trial. Anesth Analg. 2016 Oct; 123(4): 785-94.

Huupponen E, Maksimow A, Lapinlampi P et al. Electroencephalogram spindle activity during dexmedetomidine sedation and physiological sleep. Acta Anaesthesiol Scand. 2008 Oct; 52(9): 289-94.

Frölich MA, Arabshahi A, Katholi C et al. Dexmedetomidine versus Morphine Sulfate for Treatment of Acute Pain in Patients with Traumatic Rib Fractures: A Randomized, Double-Blind, Prospective Study. Clin J Pain. 2016 Aug; 32(8): 597-602.

Kallio A, Scheinin H, Koulu M et al. Effects of dexmedetomidine, a selective alpha 2-adrenoceptor agonist, on hemodynamic control mechanisms. Clin Pharmacol Ther. 1989 Nov; 46(5): 581-9.

Gerlach AT, Murphy CV, Dasta JF. An updated focused review of dexmedetomidine in adults. Ann Pharmacother. 2009 Sep; 43(9): 1471-84.

Zhao X, Han J, Jiang Y et al. Intravenous infusion of dexmedetomidine combined isoflurane inhalation reduces oxidative stress and inflammation in patients undergoing craniotomy: A randomized controlled trial. Medicine (Baltimore). 2020 Aug; 99(35): e21663.

Abraham J, Abergel RP, Haddad FJJ et al. Ultra-rapid opiate detoxification: A review. Lancet. 1996 Oct; 348(9033): 1079-82.

Nelson LE. Procedural Sedation: A Review of Sedative Agents, Monitoring, and Management of Complications. Acad Emerg Med. 2021 Apr; 28(4): 439-448.

Bajwa SJ, Dexmedetomidine and its clinical applications in intensive care units. Indian J Anaesth. 2017 Jun; 61(6): 482-488.

Bilotta F, Qeva E, Matot I. The use of dexmedetomidine in anesthesia and intensive care: A narrative review of 2013 through 2015. Aus Crit Care. 2016 May; 29(2): 79-90.